The value of adjuvant chemotherapy in stage Ⅰ endometrioid adenocarcinoma after surgery

GAO Min,WANG Li,JIANG Guo-qing,YAN Xin,ZHENG Hong,WANG Wen,GAO Yu
DOI: https://doi.org/10.3969/j.issn.1007-3639.2009.04.012
2009-01-01
Abstract:Background and purpose:The prognosis of patients with FIGO stage I endometrioid adenocarcinoma is good, although the local control is high, some patients are not sensitive to the treatment and relapse. This paper was to explore the prognostic factors associated with recurrence and assess the efficacy of adjuvant chemotherapy in patients with the FIGO stage Ⅰ endometrioid adenocarcinoma. Methods:A retrospective analysis of 96 patients with FIGO stage Ⅰ endometrioid adenocarcinoma was performed. All patients underwent surgery, of which 17 patients underwent adjuvant chemotherapy. Multivariate analysis was performed for the prognostic factors and actuarial techniques were used for recurrence rates. All the patients were followed up and the mean time of followup was 43.6±24.0 months. Results:Ten of 96 cases with FIGO stage Ⅰ endometrioid adenocarcinoma were recurrent and the recurrence rate was 10.4%. The median time of recurrence was 17.3±8.0 months. The median age was 61.8±6.4 years in recurrent patients, which was higher than that of patients without recurrence (P=0.015). In recurrent patients, the percentages of stage Ic and G3 were higher than those of other stages and histological grades (P=0.011, P=0.000). Multivariate analysis showed that FIGO stage and histological grade were significant prognostic factors (P=0.013, P=0.000). The recurrent rate in patients with FIGO stage Ic who had received postoperative adjuvant chemotherapy was significantly lower than that of patients who had not undergone adjuvant chemotherapy (P=0.046). Conclusion: FIGO stage/depth of myometrial invasion and histological grade were important prognostic factors in FIGO stage Iendometrioid adenocarcinoma. It is possible that postoperative adjuvant chemotherapy might decrease the recurrence and improve the prognosis in patient with stage Ic.
What problem does this paper attempt to address?